PD-217,014

PD-217,014 is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α 2 δ calcium channels (1 and 2).

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

PD-217,014 is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α 2 δ calcium channels (1 and 2). It was developed as a potentially more potent successor to gabapentin and pregabalin, along with several other analogues such as atagabalin and 4-methylpregabalin, but while PD-217,014 produces visceral analgesic effects in animal studies with higher potency and efficacy than gabapentin, it was not developed further for clinical use because of its comparatively more complex synthesis, compared to other related analogues.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1377083197 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.